Braham Shroot

Dr. Shroot brings over 30 years of experience in drug research and development specializing in skin disorders, and played a key role in the development of commercially available therapeutics including Differin, Atralin, Vectical, and Diflucan.

Dr. Shroot is the recipient of the American Skin Association’s Lifetime Achievement Award and an honorary lifetime member of the Society for Investigative Dermatology. Prior to Palvella, Dr. Shroot held senior roles in the biopharma industry, including President of Galderma Research, Chief Scientific Officer of Barrier Therapeutics (sold to Stiefel), and CSO/VP of R&D for DFB Pharmaceuticals. Dr. Shroot also served as the chief executive officer of Signum Biosciences, a company developing dermatological therapeutics. Dr. Shroot is an inventor on over 50 patents, author of over 260 publications, and a member of the editorial boards of several prestigious dermatology journals. Dr. Shroot earned a B.Sc. in Chemistry and a Ph.D. in Organic Chemistry from Glasgow University in Scotland.